Sanofi Consumer Healthcare (SCHIL) provided an investor presentation outlining its strategy for re-igniting profitable growth following its recent organizational separation. The presentation highlighted strong FY 2025 data, including ₹8784 Mn in revenue and 36.7% profit from operations, driven by brand equity and unlocking new demand levers. The roadmap focuses on scaling HCP engagement, consumer reach, and improving market access through an empowered management structure and leveraging Digital & AI.
Company Snapshot and Recent Performance
Sanofi Consumer Healthcare presented a snapshot of its performance, noting significant financial achievements based on FY 2025 Data (Pre Recall, Source: IQVIA MAT Dec’25):
- Revenue from operations: ₹8784 Mn
- Profit from operations: 36.7%
- ROCE: 62.5%
The company highlighted its Leading Brands, including Avil (#1 vol), Allegra (#3 val), Combiflam (#5 vol), and DePura (#5#).
Overall performance leading to this presentation showed strong year-over-year growth versus FY 2024:
- Revenue from operations: +21%
- Operating Profit: +13%
- Profit After Tax: +33%
Strategic Separation and Evolution
The presentation detailed the organization’s journey, which included a turbulent start encompassing the hiving off of the Nutra business (2021), manpower rationalization (2022), demerger (Jun 2024), and successful listing (Sep 2024). A key philosophical shift was detailed, contrasting the Pharma Approach (win with patented formulations, prescription driven) with the Consumer Healthcare Approach (Win on Brand Equity, sustained investments in brand building).
A core initial challenge was identified as constrained demand generation, where current brand coverage across Allegra, Combiflam, DePURA, and Avil was limited to Health Care Professionals, lacking traction with Consumers and Point of Sale for most products. This gap is being addressed by unlocking demand levers for Allergy, Pain, and Vit D categories.
The Road Ahead: Our Strategy
The overarching strategy is defined by the MISSION: “Health. In your hands. By making selfcare as simple as it should be,” with the VISION to “Become the best FMCH In & For India.”
The strategic pillars for execution are:
- Scale HCP Initiation.
- Scale Consumer Engagement.
- Improve Access.
This is being realized through core enablers under MAKING IT HAPPEN:
- Right Talent x Performance Culture (attracting best-in-class FMCH talent, fostering a performance-driven culture).
- Digital & AI (leveraging data for prescriptive analysis and agile visuals).
- Lean & efficient supply chain.
Scaling HCP and Consumer Engagement
To scale HCP recommendations, the company targets 2X Doctor reach Face to Face and +50K Doctor reach on DIGITAL.
Digital-first demand generation focuses on a ~60 Mn multi-media reach, with targeted spends on Social to drive influence by ~30%. This supports growth in categories where significant headroom exists, such as Pain (where ~9/10 experienced an episode) and Vit D (where ~7/10 Indians are deficient).
Improving Access
Access improvements involve increasing direct retail coverage and chemist recommendations, aiming for a 2X direct coverage increase to win at the store level.
Empowered Execution
The organization is moving toward Empowered Country Management, focusing on:
- Adopting an India – first approach to innovations for global brands.
- Achieving Complete ownership of Global Brand P&L.
- Utilizing a Dedicated in house ai creative team for India.
Finally, the company highlighted its commitment to society and the planet, including achieving B CORP CERTIFICATION and executing projects like PROJECT AMRIT (benefiting >190K people) and VAN MITRA (planting 34K trees annually).
Source: BSE
